Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. by Titulaer, M, Lang, B, Verschuuren, J

Clinical aspects of myasthenia explained. by Verschuuren, J, Palace, J, Gilhus, N

Guidelines for pre-clinical animal and cellular models of MuSK-myasthenia gravis. by Phillips, W, Christadoss, P, Losen, M, Punga, A, Shigemoto, K, Verschuuren, J, Vincent, A

HLA-B8 in patients with the Lambert-Eaton myasthenic syndrome reduces likelihood of associated small cell lung carcinoma. by Wirtz, P, Willcox, N, Roep, B, Lang, B, Wintzen, A, Newsom-Davis, J, Verschuuren, J

Risk of Fracture in Patients with Myasthenia Gravis by Bazelier, M, Pouwels, S, Javaid, K, Cooper, C, Hilton-Jones, D, Verschuuren, J, van Staa, T, De Vries, F

Fracture rate in patients with myasthenia gravis: the general practice research database. by Pouwels, S, de Boer, A, Javaid, M, Hilton-Jones, D, Verschuuren, J, Cooper, C, Leufkens, H, de Vries, F

THE UTILITY OF SOX ANTIBODIES FOR CANCER PREDICTION IN PATIENTS WITH PARANEOPLASTIC NEUROLOGICAL DISORDERS by Maddison, P, Titulaer, M, Verschuuren, J, Gozzard, P, Lang, B, Willcox, N, Vincent, A, Irani, SR, Chapman, C

Fracture rate in patients with myasthenia gravis: the general practice research database by Pouwels, S, de Boer, A, Javaid, M, Hilton-Jones, D, Verschuuren, J, Cooper, C, Leufkens, H, de Vries, F

The utility of anti-SOX2 antibodies for cancer prediction in patients with paraneoplastic neurological disorders by Maddison, P, Titulaer, M, Verschuuren, J, Gozzard, P, Lang, B, Irani, S, Sabater, L, Graus, F, Murray, A, Chapman, C

Strong association of MuSK antibody-positive myasthenia gravis and HLA-DR14-DQ5. by Niks, E, Kuks, J, Roep, B, Haasnoot, G, Verduijn, W, Ballieux, B, De Baets, M, Vincent, A, Verschuuren, J

P/Q-type calcium channel antibodies, Lambert-Eaton myasthenic syndrome and survival in small cell lung cancer. by Wirtz, P, Lang, B, Graus, F, van den Maagdenberg, A, Saiz, A, de Koning Gans, P, Twijnstra, A, Verschuuren, J

Guidelines for the treatment of autoimmune neuromuscular transmission disorders. by Skeie, G, Apostolski, S, Evoli, A, Gilhus, N, Hart, I, Harms, L, Hilton-Jones, D, Melms, A, Verschuuren, J, Horge, H

A transient neonatal myasthenic syndrome with anti-musk antibodies. by Niks, E, Verrips, A, Semmekrot, B, Prick, M, Vincent, A, van Tol, M, Jol-van der Zijde, C, Verschuuren, J

Guidelines for treatment of autoimmune neuromuscular transmission disorders. by Skeie, G, Apostolski, S, Evoli, A, Gilhus, N, Illa, I, Harms, L, Hilton-Jones, D, Melms, A, Verschuuren, J, Horge, H

Autoimmune Neuromuscular Transmission Disorders by Skeie, G, Apostolski, S, Evoli, A, Gilhus, N, Illa, I, Harms, L, Hilton-Jones, D, Melms, A, Verschuuren, J, Westgaard Horge, H

AChR deficiency due to epsilon-subunit mutations: two common mutations in the Netherlands. by Faber, C, Molenaar, P, Vles, J, Bonifati, D, Verschuuren, J, van Doorn, P, Kuks, J, Wokke, J, Beeson, D, De Baets, M

HLA and smoking in prediction and prognosis of small cell lung cancer in autoimmune Lambert-Eaton myasthenic syndrome. by Wirtz, P, Willcox, N, van der Slik, A, Lang, B, Maddison, P, Koeleman, B, Giphart, M, Wintzen, A, Roep, B, Verschuuren, J

The effect of plasma from muscle-specific tyrosine kinase myasthenia patients on regenerating endplates. by ter Beek, W, Martínez-Martínez, P, Losen, M, de Baets, M, Wintzen, A, Verschuuren, J, Niks, E, van Duinen, S, Vincent, A, Molenaar, P

Recommended diagnostic criteria for paraneoplastic neurological syndromes. by Graus, F, Delattre, J, Antoine, J, Dalmau, J, Giometto, B, Grisold, W, Honnorat, J, Smitt, P, Vedeler, C, Verschuuren, J, Vincent, A, Voltz, R

Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1. by Niks, E, van Leeuwen, Y, Leite, M, Dekker, F, Wintzen, A, Wirtz, P, Vincent, A, van Tol, M, Jol-van der Zijde, C, Verschuuren, J